Targeting insulin-like growth factor 1 receptor in sarcomas

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 419-427

  Scotlandi, Katia ^a   Picci, Piero ^a  

^a Laboratory of Oncologic Research   (Italy)

Author keywords

Biomarkers; Insulin like growth factor I receptor; Metabolism; Sarcomas; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; CP 751871; IMC A12; INSULIN RECEPTOR; LIGNAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; NORDIHYDROGUAIARETIC ACID; PHOSPHOTRANSFERASE INHIBITOR; PICOPODOPHYLLIN; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; RNA BINDING PROTEIN EWS; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG;

CANCER INHIBITION; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; DRUG TARGETING; GENETIC VARIABILITY; HUMAN; METASTASIS; NONHUMAN; OSTEOSARCOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; SARCOMA; SIGNAL TRANSDUCTION; TUMOR; UPREGULATION; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANTINEOPLASTIC AGENTS; HUMANS; RECEPTOR, IGF TYPE 1; SARCOMA; SIGNAL TRANSDUCTION;

EID: 47249106539     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328302edab     Document Type: Review

References (75)

1. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005; 9:753-768.
2. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1-12. A comprehensive review on the strategies targeting IGF-IR, with emphasis on bad and good points
3. Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28:20-47. An outstanding and comprehensive review on the mechanisms of action of the IGF system in cancer.
4. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-518. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13:748-753.
5. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002; 1:769-783.
6. Laviola L, Perrini S, Cignarelli A, et al. Insulin signalling in human adipose tissue. Arch Physiol Biochem 2006; 112:82-88.
7. Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des 2007; 13:663-669.
8. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13:671-686. An extensive review on the potential roles of insuling signaling and HR in cancer.
9. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19:3278-3288.
10. Rubinstein M, Idelman G, Plymate SR, et al. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53. Endocrinology 2004; 145:3769-3777.
11. Sarfstein R, Maor S, Reizner N, et al. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 2006; 252:241-246.
12. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002; 175: 19-31.
13. Werner H, Idelman G, Rubinstein M, et al. A novel EWS-WT1 gene fusion product in desmoplastic small round cell tumor is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene. Cancer Lett 2007; 247:84-90.
14. Karnieli E, Werner H, Rauscher FJ 3rd, et al. The IGF-I receptor gene promoter is a molecular target for the Ewing's sarcoma-Wilms' tumor 1 fusion protein. J Biol Chem 1996; 271:19304-19309.
15. Ayalon D, Glaser T, Werner H. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Growth Horm IGF Res 2001; 11:289-297.
16. Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabdomyosarcoma. J Clin Invest 1994; 94:445-448.
17. Zhang L, Zhan S, Navid F, et al. AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma. Oncogene 1998; 17:1261-1270.
18. Sun Y, Gao D, Liu Y, et al. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006; 25:1042-1052.
19. de Bruijn DR, Allander SV, van Dijk AH, et al. The synovial-sarcoma- associated SS18-SSX2 fusion protein induces epigenetic gene (de) regulation. Cancer Res 2006; 66:9474-9482.
20. Riggi N, Cironi L, Provero P, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res 2005; 65:11459-11468.
21. Prieur A, Tirode F, Cohen P, et al. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004; 24:7275-7283.
22. Chang Q, Li Y, White MF, et al. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. Cancer Res 2002; 62:6035-6038.
23. Silvany RE, Eliazer S, Wolff NC, et al. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 2000; 19:4523-4530.
24. Benini S, Manara MC, Cerisano V, et al. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004; 108:358-366. of special interest of outstanding interest Additional references related to this topic can also be found in the Current World Literature section in this issue (p. 478).
25. Pinski J, Schally AV, Groot K, et al. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 1995; 87:1787-1794.
26. Kappel CC, Velez-Yanguas MC, Hirschfeld S, et al. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 1994; 54:2803-2807.
27. Benini S, Baldini N, Manara MC, et al. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer 1999; 80:581-588.
28. MacEwen EG, Pastor J, Kutzke J, et al. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 2004; 92:77-91.
29. Kirpensteijn J, Timmermans-Sprang EP, van Garderen E, et al. Growth hormone gene expression in canine normal growth plates and spontaneous osteosarcoma. Mol Cell Endocrinol 2002; 197:179-185.
30. Viereck V, Siggelkow H, Pannem R, et al. Alteration of the insulin-like growth factor axis during in vitro differentiation of the human osteosarcoma cell line HOS 58. J Cell Biochem 2007; 102:28-40.
31. Savage SA, Woodson K, Walk E, et al. Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomarkers Prev 2007; 16:1667-1674. First study identifying the contribution of common genetic variants in the IGF system to sarcoma risk.
32. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996; 56:4570-4574.
33. Toretsky JA, Kalebic T, Blakesley V, et al. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997; 272:30822-30827.
34. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007; 254:1-10.
35. Wang W, Kumar P, Wang W, et al. Insulin-like growth factor II and PAX3-FKHR cooperate in the oncogenesis of rhabdomyosarcoma. Cancer Res 1998; 58:4426-4433.
36. Xu Q, Wu Z. The insulin-like growth factor-phosphatidylinositol 3-kinase-Akt signaling pathway regulates myogenin expression in normal myogenic cells but not in rhabdomyosarcoma-derived RD cells. J Biol Chem 2000; 275:36750-36757.
37. Tsuchiya K, Hosoi H, Misawa-Furihata A, et al. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells. Int J Oncol 2007; 31:41-47.
38. Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 1998; 69:21-27.
39. Xie Y, Skytting B, Nilsson G, et al. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999; 59:3588-3591.
40. de Alava E, Panizo A, Antonescu CR, et al. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000; 156:849-855.
41. Busund LT, Ow KT, Russell P, et al. Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Arch 2004; 444:142-148.
42. Ahlen J, Wejde J, Brosjo O, et al. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma. Clin Cancer Res 2005; 11:206-216.
43. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 1994; 54:5531-5534.
44. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998; 58:4127-4131.
45. Kalebic T, Blakesley V, Slade C, et al. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 1998; 76:223-227.
46. Scotlandi K, Maini C, Manara MC, et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002; 9:296-307.
47. Scotlandi K, Avnet S, Benini S, et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int J Cancer 2002; 101:11-16.
48. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64:236-242.
49. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5:231-239.
50. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65:3868-3876.
51. Benini S, Zuntini M, Manara MC, et al. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma. Int J Cancer 2006; 119:1039-1046.
52. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12:3532-3540.
53. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007; 13:1322-1330. The study evaluated the effects of an anti-IGF-IR TK inhibitor on migration, vasculogenesis and metastases. Potential side effects were also considered.
54. Kull FC Jr, Jacobs S, Su YF, et al. Monoclonal antibodies to receptors for insulin and somatomedin-C. J Biol Chem 1983; 258:6561-6566. Feng Y, Mimitrov DS. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 2008; 11:178-185. An updated and comprehensive overview of the different monoclonal antibodies against IGF-IR that have been developed. Unique features and results obtained from clinical trials are reviewed.
55. Sachdev D, Li SL, Hartell JS, et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63:627-635.
56. Rubini M, Hongo A, D'Ambrosio C, et al. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 1997; 230:284-292.
57. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5:221-230.
58. Vasilcanu R, Vasilcanu D, Rosengren L, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008; 27:1629-1638.
59. Zavodovskaya M, Campbell MJ, Maddux BA, et al. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem 2008; 103:624-635.
60. Lu Y, Zi X, Zhao Y, et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93:1852-1857.
61. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005; 41:1349-1361.
62. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-5555s. The first published report on a phase I trial using a humanized anti IGF-IR antibody.
63. Benini S, Manara MC, Baldini N, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001; 7:1790-1797.
64. Manara MC, Perdichizzi S, Serra M, et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol 2005; 27:1605-1616.
65. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508.
66. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26:1932-1940.
67. Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004; 90:1825-1829.
68. Terry J, Lubieniecka JM, Kwan W, et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005; 11:5631-5638.
69. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006; 20:1254-1260.
70. Petricoin EF 3rd, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007; 67:3431-3440. The study identifies the relationship between Akt/mTOR and IGF-IR pathways and correlates expression of significant mediators with prognosis of rhabdomyosarcoma patients. Insulin-like growth factor 1 receptor in sarcomas Scotlandi and Picci 427
71. Vasilcanu D, Weng WH, Girnita A, et al. The insulin-like growth factor-1 receptor inhibitor PPP produces only very limited resistance in tumor cells exposed to long-term selection. Oncogene 2006; 25:3186-3195.
72. Jackson JG, Zhang X, Yoneda T, et al. Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines. Oncogene 2001; 20:7318-7325.
73. Nagle JA, Ma Z, Byrne MA, et al. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 2004; 24:9726-9735.
74. Zhang X, Kamaraju S, Hakuno F, et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004; 83:161-170.
75. Shefi-Friedman L, Wertheimer E, Shen S, et al. Increased IGFR activity and glucose transport in cultured skeletal muscle from insulin receptor null mice. Am J Physiol Endocrinol Metab 2001; 281:E16-E24.